Andrew H. Lane - 15 Nov 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: EXECUTIVE VICE PRESIDENT
Issuer ticker: ABT
Reported as of: 15 Nov 2021
Net transaction value: -$1,300,090
SEC form: 4
Accepted by SEC: 17 Nov 2021, 17:22:31 UTC
Prior SEC filing: 31 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Andrew H. Lane by Jessica H. Paik, Attorney-in-Fact, Attorney-in-Fact

Key filing fact

Andrew H. Lane filed Form 4 for ABBOTT LABORATORIES (ABT) on 17 Nov 2021.

Key facts

This page summarizes Andrew H. Lane's Form 4 filing for ABBOTT LABORATORIES (ABT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Nov 2021, 17:22.

Change

Previous filing in this sequence was filed on 31 Aug 2021.
Current net transaction value: -$1,300,090.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Sale

Transaction value: $1,300,090
Shares: -10,000
Change %: -12%
Price: $130.01
Shares after: 76,087
Date: 15 Nov 2021
Ownership: Direct
Footnotes: F1

ABT holding

Common shares without par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,543
Date: 15 Nov 2021
Ownership: Profit Sharing Trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F2

Balance in the Abbott Laboratories Stock Retirement Trust as of November 15, 2021.

SEC remarks

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).